000 02039 a2200601 4500
005 20250515160020.0
264 0 _c20091207
008 200912s 0 0 eng d
022 _a1468-1293
024 7 _a10.1111/j.1468-1293.2008.00660.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aYeni, P
245 0 0 _aAntiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136).
_h[electronic resource]
260 _bHIV medicine
_cFeb 2009
300 _a116-24 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aBenzoates
_xpharmacokinetics
650 0 4 _aDiketopiperazines
650 0 4 _aDrug Administration Schedule
650 0 4 _aDrug Therapy, Combination
650 0 4 _aFemale
650 0 4 _aHIV Infections
_xdrug therapy
650 0 4 _aHIV Protease Inhibitors
_xpharmacokinetics
650 0 4 _aHIV-1
_ximmunology
650 0 4 _aHumans
650 0 4 _aLopinavir
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aPiperazines
_xpharmacokinetics
650 0 4 _aPyrimidinones
_xpharmacokinetics
650 0 4 _aRNA, Viral
_ximmunology
650 0 4 _aReceptors, CCR5
_xtherapeutic use
650 0 4 _aRitonavir
_xpharmacokinetics
650 0 4 _aSpiro Compounds
_xpharmacokinetics
650 0 4 _aYoung Adult
700 1 _aLamarca, A
700 1 _aBerger, D
700 1 _aCimoch, P
700 1 _aLazzarin, A
700 1 _aSalvato, P
700 1 _aSmaill, F M
700 1 _aTeofilo, E
700 1 _aMadison, S J
700 1 _aNichols, W G
700 1 _aAdkison, K K
700 1 _aBonny, T
700 1 _aMillard, J
700 1 _aMcCarty, D
773 0 _tHIV medicine
_gvol. 10
_gno. 2
_gp. 116-24
856 4 0 _uhttps://doi.org/10.1111/j.1468-1293.2008.00660.x
_zAvailable from publisher's website
999 _c18644431
_d18644431